Limor Zur-Stoller
Geen lopende functies
Profiel
Limor Zur-Stoller served as Vice President-Finance & Investor Relations at RadView Software Ltd.
She was also Chief Financial Officer & Treasurer at Gammacan International, Inc. from 2008 to 2011.
From 2008 to 2010, she held the position of Vice President-Finance at Rosetta Genomics Ltd.
Later, she served as Chief Financial Officer & IR Contact at G.F.C Green Fields Capital Ltd.
from 2012 to 2015.
Zur-Stoller completed her undergraduate degree from Tel-Aviv University.
Eerdere bekende functies van Limor Zur-Stoller
| Bedrijven | Functie | Einde |
|---|---|---|
| ROSETTA GENOMICS LTD. | Financieel Directeur/CFO | 01-10-2010 |
| G.F.C GREEN FIELDS CAPITAL LTD. | Financieel Directeur/CFO | - |
Gammacan International, Inc.
 Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | Financieel Directeur/CFO | - |
| RADVIEW SOFTWARE LTD. | Financieel Directeur/CFO | - |
Opleiding van Limor Zur-Stoller
| Tel-Aviv University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| RADVIEW SOFTWARE LTD. | Technology Services |
| ROSETTA GENOMICS LTD. | Health Technology |
| G.F.C GREEN FIELDS CAPITAL LTD. | Finance |
| Bedrijven in privébezit | 1 |
|---|---|
Gammacan International, Inc.
Gammacan International, Inc. Medical SpecialtiesHealth Technology Gammacan International, Inc. operates as a life sciences company. The company focuses on the development of immunotherapy and related approaches to treat cancer. It also focuses on the use of intravenous immunoglobulin derived from human plasma provided by healthy donors to treat melanoma, prostate, and colon cancers. The company was founded on October 6, 1998 and is headquartered in Kiryat Ono, Israel. | Health Technology |
